Use of sodium oxybate (Xyrem®) in patients with dual diagnosis of narcolepsy and sleep apnea

Sleep Medicine

Volumn 11, Issue 1, 2010, Pages 5-6

  Kovačević Ristanović, Ružica ^a   Kuźniar, Tomasz J ^a  

^a NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MODAFINIL; OXYBATE SODIUM; PLACEBO; ZOLPIDEM;

BEDTIME DOSAGE; CATAPLEXY; CLINICAL TRIAL; COMA; COMORBIDITY; DAYTIME SOMNOLENCE; DECISION MAKING; DOSE RESPONSE; DRUG ABSORPTION; DRUG FATALITY; EDITORIAL; FATTY ACID DESATURATION; FOOD; FOOD DRUG INTERACTION; HUMAN; NARCOLEPSY; OXIMETRY; OXYGEN SATURATION; POLYSOMNOGRAPHY; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REM SLEEP; RESPIRATION DEPRESSION; RESPIRATORY FUNCTION; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP APNEA SYNDROME; SLEEP DISORDER; SLOW WAVE SLEEP;

ADJUVANTS, ANESTHESIA; COMBINED MODALITY THERAPY; CONTINUOUS POSITIVE AIRWAY PRESSURE; DIAGNOSIS, DUAL (PSYCHIATRY); DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; NARCOLEPSY; POLYSOMNOGRAPHY; SLEEP APNEA, OBSTRUCTIVE; SODIUM OXYBATE;

EID: 73249124163     PISSN: 13899457     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sleep.2009.09.001     Document Type: Editorial

References (14)

1. Xyrem International Study Group. A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy. J Clin Sleep Med 2005; 1(4): 391-7.
2. Xyrem International Study Group. Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind, placebo-controlled study in 228 patients. Sleep Med 2005; 6(5): 415-21.
3. Morgenthaler T.I., Kapur V.K., Brown T., et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep 30 12 (2007) 1705-1711
4. Mamelak M., Black J., Montplaisir J., and Ristanovic R. A pilot study on the effects of sodium oxybate on sleep architecture and daytime alertness in narcolepsy. Sleep 27 7 (2004) 1327-1334
5. Lapierre O., Montplaisir J., Lamarre M., and Bedard M.A. The effect of gamma-hydroxybutyrate on nocturnal and diurnal sleep of normal subjects: further considerations on REM sleep-triggering mechanisms. Sleep 13 1 (1990) 24-30
6. Kintz P., Villain M., Pelissier A.L., Cirimele V., and Leonetti G. Unusually high concentrations in a fatal GHB case. J Anal Toxicol 29 6 (2005) 582-585
7. Akins B.E., Miranda E., Lacy J.M., and Logan B.K. A multi-drug intoxication fatality involving Xyrem (GHB). J Forensic Sci 54 2 (2009) 495-496
8. Zvosec D.L., Smith S.W., and Hall B.J. Three deaths associated with use of Xyrem. Sleep Med 10 4 (2009) 490-493
9. Wang YG, Swick TJ, Carter LP, Thorpy MJ, Benowitz NL. Safety overview of postmarketing and clinical experience of sodium oxybate (Xyrem): abuse, misuse, dependence, and diversion. J Clin Sleep Med (in press). Available at http://www.aasmnet.org/jcsm/AcceptedPapers/JC-022-09.pdf.
10. Xyrem (R) (sodium oxybate) oral solution. Package insert. http://jazzph.isat-tech.com/media/PI.pdf, Date accessed: August 2, 2009.
11. Santamaria J., Sansa G., and Iranzo A. Prevalence and clinical relevance of sleep apnea in narcolepsy. Sleep 30 Suppl. (2007) A224-A225
12. Series F., Series I., and Cormier Y. Effects of enhancing slow-wave sleep by gamma-hydroxybutyrate on obstructive sleep apnea. Am Rev Respir Dis 145 6 (1992) 1378-1383
13. Seeck-Hirschner M., Baier P.C., von Freier A., Aldenhoff J., and Goder R. Increase in sleep-related breathing disturbances after treatment with sodium oxybate in patients with narcolepsy and mild obstructive sleep apnea syndrome: two case reports. Sleep Med 10 1 (2009) 154-155
14. George C.F.P., Feldman N., Inhaber N., et al. A safety trial of sodium oxybate in patients with obstructive sleep apnea: acute effects on sleep-disordered breathing. Sleep Med 11 1 (2010) 38-42